Kymera provides clinical update on KT-474 Phase 1 Part C in HS & AD; oncology pipeline update

Kymera Therapeutics, Inc.

Held virtual investor event to present Part C Phase 1 data for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis.
Also discussed updates on the company's oncology pipeline programs.
Full presentation furnished as Exhibit 99.1; no specific numerical results disclosed in the filing text.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.